Novo Nordisk CEO Mike Doustdar is challenging the widely held investor view that the booming obesity drug market can only produce one clear winner.
Speaking to Reuters in an interview published Thursday, Doustdar argued that patients are still discovering their preferences in the fast-growing GLP-1 weight loss space.
He suggested that as more obesity drugs reach approval, the appetite for differentiation among patients will only increase, leaving room for multiple successful players.
Investors have largely framed the competition between Novo and its chief rival Eli Lilly (LLY) as a “zero-sum game,” but Doustdar believes that view misses the bigger picture entirely.
The CEO pointed to Novo’s own insulin business as a potential template, noting the company successfully markets 12 different insulin brands that “all reduce sugar, but they do also different things.”
In much the same way, he said, “GLP-1s all reduce weight, but they all do different things.”
Doustdar’s differentiation thesis has already found some support this year through the successful launch of Novo’s oral Wegovy pill, which launched on January 5 and quickly built a substantial sales lead over Lilly’s competing obesity oral Foundayo.
Novo reported that the Wegovy pill reached more than 5 million patients since launch, with total weekly prescriptions for the week ending July 17 coming in above 265,000.
The company attributed approximately $500 million in sales for the second quarter to the oral Wegovy, contributing to an overall obesity revenue gain of 16% and total Q2 sales of 23.15 billion Danish kroner, roughly $3.6 billion.
By contrast, Lilly’s Foundayo generated just $98 million in its second quarter, a performance that Leerink Partners analyst David Risinger described as having “disappointed” in an early August note to clients.
Despite Lilly continuing to lead across the broader US obesity market, execs there are guiding toward an “inflection point” in Foundayo’s growth trajectory going forward.
Crucially, prescription data from both companies suggests that the launch of daily obesity pills is bringing entirely new patients into the GLP-1 class rather than simply pulling sales away from existing injectable options.
That dynamic supports the broader argument that a wider obesity treatment landscape will meaningfully expand the overall prescribing pool rather than redistribute it.
Looking ahead, both Novo and Lilly have next-generation metabolic candidates in development, while pharma giants including Amgen, Roche, Pfizer, and AstraZeneca also have mid- and late-stage obesity hopefuls in the works.
At the American Diabetes Association 2026 Scientific Sessions in New Orleans, differentiation on metrics like tolerability, weight loss magnitude, and the management of obesity-related health complications emerged as a prominent theme across company presentations.
Doustdar told Fierce in a June interview that the conversation around what patients actually want from obesity drugs is shifting in a meaningful and encouraging direction.
“For the first time, I’m hearing people not talk about a single digit number on weight loss effect, but a combination of things that a patient wants,” Doustdar said in that interview.
“Better tolerability, maybe a pill instead of an injection, maybe the quality of the weight loss is the issue — all of those things that we started spending billions of dollars in, and maybe initially did not see the return, I think was the right thing.”
Novo has already moved to embrace this differentiation mindset through strategies like its “beyond weight” messaging for injectable Wegovy, which emphasises the drug’s cardiovascular risk-reduction benefits alongside its weight loss profile.